# Contact Peptide Mundo — Editorial Desk

> Reach the Peptide Mundo editorial desk regarding citations, corrections, or research-related correspondence about our Metabolic & Weight Research peptide digest.

Correspondence on citations, corrections, and research-related inquiries — the things a reference desk is most useful to hear about.

## Editorial correspondence

Peptide Mundo welcomes correspondence on the research record: a citation we have quoted inaccurately, a clinical trial that has published new results, a regulatory update that changes an approval status, or a peer-reviewed study on semaglutide, tirzepatide, or retatrutide that should be added to the [references page](/references). This class of correction — one that improves the accuracy or currency of the digest — is the most useful message this desk receives, and each is read and considered carefully.

The most actionable submissions specify: the page in question, the exact passage being corrected or challenged, and the supporting reference — a DOI or PubMed identifier wherever possible. That format allows a proposed change to be verified against its source before it is acted upon.

**Editorial mailbox:** editors@peptidemundo.com

## What this desk cannot do

So that no message goes unanswered for the wrong reason, a few things fall outside what this site can address. Peptide Mundo is a literature digest, not a clinical service or product vendor, so it cannot:

- Advise on, recommend, or comment on human use of any peptide discussed here.
- Suggest a dose, schedule, or route of administration for any individual.
- Evaluate whether a research finding from a cited trial applies to a specific person's situation.
- Sell, source, recommend, or help locate any compound from any supplier.
- Provide information on obtaining prescription medicines outside of a licensed prescriber-patient relationship.
- Advise athletes subject to anti-doping rules, given that some compounds in this class have pharmacovigilance profiles that intersect with WADA monitoring.

Semaglutide and tirzepatide are prescription medicines. Retatrutide is an investigational compound not legally available outside clinical trials. Readers seeking medical guidance should consult a licensed clinician in their jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.

---

A peer-reviewed literature digest on incretin-class metabolic peptides — citations and context, not clinical counsel.